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Abstract Cell misidentification and cross-contamination
have plagued biomedical research for as long as cells have
been employed as research tools. Examples of misidentified
cell lines continue to surface to this day. Efforts to eradicate
the problem by raising awareness of the issue and by asking
scientists voluntarily to take appropriate actions have not
been successful. Unambiguous cell authentication is an
essential step in the scientific process and should be an
inherent consideration during peer review of papers
submitted for publication or during review of grants
submitted for funding. In order to facilitate proper identity
testing, accurate, reliable, inexpensive, and standardized
methods for authentication of cells and cell lines must be
made available. To this end, an international team of
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DOI 10.1007/s11626-010-9333-zscientists is, at this time, preparing a consensus standard on
the authentication of human cells using short tandem repeat
(STR) profiling. This standard, which will be submitted for
review and approval as an American National Standard by
the American National Standards Institute, will provide
investigators guidance on the use of STR profiling for
authenticating human cell lines. Such guidance will include
methodological detail on the preparation of the DNA
sample, the appropriate numbers and types of loci to be
evaluated, and the interpretation and quality control of the
results. Associated with the standard itself will be the
establishment and maintenance of a public STR profile
database under the auspices of the National Center for
Biotechnology Information. The consensus standard is
anticipated to be adopted by granting agencies and
scientific journals as appropriate methodology for authen-
ticating human cell lines, stem cells, and tissues.
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Introduction
Animal and human primary cell cultures, continuous (immor-
talized)celllines,andtissues areofoverwhelmingimportance
to the biopharmaceutical industry and to biomedical research
as reagents, therapeutic modalities, and as proxy materials for
the study of more complex physiological systems. Cell
cultures have, from the beginning, been at risk for misiden-
tification due to labeling errors, incorrect classification by
pathologists, and cross-contamination with other cell types.
Continuous cell lines are potentially jeopardized due to the
extended time these are in culture and the frequent manipu-
lations involved in the course of feeding and subculturing.
Human stem cell preparations which are propagated in the
presence of non-human feeder cell layers are at risk of cross-
contamination with the feeder cells. Tumor cells propagated
by xenografting onto host animals are at risk of cross-
contamination with the host cells.
We know the risks involved in establishing and maintain-
ing cell cultures. We know that periodic identity testing
(authentication) is the only way to prove that the cell we are
studying is the cell that we believe it to be, and not a
contaminating tumor cell line such as HeLa. Why then are
many investigators blindly assuming that they are using
correctly identified cells? Recent publications appear to
indicate that the problem of cell misidentification is not going
away. For instance, Berglind et al. (2008)e v a l u a t e dt h ep 5 3
status of 1,211 cell lines published between 1989 and 2007
and found discrepancies in the p53 status for 23% of the cell
lines. Schweppe et al. (2008) evaluated 40 human thyroid
cancer cell lines and found that only 23 of these actually had
unique genetic profiles, as determined using short tandem
repeat (STR) profiling and single nucleotide polymorphism
analysis. Certain of the presumed thyroid cancer cell lines
were found to have profiles matching colon cancer or
melanoma cells. Another recent revelation was that of
Boonstra et al. (2010) indicating that three widely used
esophageal cancer cell lines are, in fact, derived from other
tumor types. Dittmar et al. (2010)h a v er e p o r t e dt w on e w
cases of misidentification of supposed human cells. Their
work clearly demonstrates that phenotypic evaluation alone
cannot provide adequate assurance of the authenticity of a
cell line. More extensive lists of misidentified cells are
available from a number of sources (e.g., ATCC SDO
Workgroup ASN-0002 2010; Capes-Davis et al. 2010).
Within the highly regulated biopharmaceutical industry,
cell lines used as production substrates must be characterized
for identity through phenotypic analysis and confirmation of
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728 BARALLON ET AL.animal species of origin (US FDA 1993). This, together with
implementation of current good manufacturing practices, is
believed to have contributed to the relatively low frequency
of cell line misidentification reported in this industry (Nims
and Herbstritt 2005).
Remediation of the problem of cell line misidentification
within the biomedical research community may eventually
need to be driven by requirements for authentication from
granting agencies and journal editors. An international
group of scientists is now preparing a consensus standard
which will provide investigators with guidance on the
appropriate methodology for authenticating human cells. In
this article, we describe the rationale for and the process
involved in preparing this standard.
Efforts to Remediate the Problem of Cell
Misidentification
The earliest efforts toward tackling the problem of cell
misidentification centered on disclosure of the issue
through conference presentations and publications. Gartler
(e.g., Gartler 1967) and Nelson-Rees (e.g., Nelson-Rees et
al. 1974) were among the first and most vocal of those
attempting to convince the scientific community of the
seriousness of the issue. They hoped that such disclosures
would motivate scientists to voluntarily take actions to
remediate the problem.
More recently, Roland Nardone championed a series of
efforts intended to reemphasize the seriousness of the cell
misidentificationproblemandtakeanyrequiredstepstobegin
remediating the various causes for the continuing issue. His
efforts began with the authoring of a white paper, entitled
“Eradication of Cross-Contaminated Cell Lines: A Call for
Action” (Nardone 2007). This paper presented recommenda-
tions for strict compliance measures in addition to continuing
efforts to educate scientists. Nardone believed the time had
come for granting agencies to demand cell line authentica-
tion as a condition for the receipt of funds and for journals to
add a similar requirement to their instructions for authors for
manuscripts submitted for publication.
As part of his efforts to convince granting agencies of
the need for their participation in his overall remediation
strategy, Nardone and a group of prominent cell scientists
composed and signed an open letter to Michael O. Leavitt,
Secretary of Health and Human Resources (Nardone et al.
2007), beseeching the NIH to take appropriate actions. On
November 28, 2007, the NIH published an addition to their
Guidelines for Research—Notice Regarding Authentication
of Cultured Cell Lines (National Institutes of Health 2007)
calling for diligence and more careful peer review.
Communications between Nardone (and others) and
journal editors have achieved the desired result as slowly
and surely, journals are beginning to add the requirement
for cell authentication to their instructions for authors (e.g.,
Cell Biochemistry and Biophysics, In Vitro Cellular &
Developmental Biology—Animal, International Journal of
Cancer, and the journals of the American Association for
Cancer Research).
Attempts to educate scientists in general of the need for
cell authentication must go beyond simply raising the level
of awareness of the problem. In his white paper, Nardone
also stressed the need for training in cell authentication to
be added to conference agendas. He recommended that
societies sponsor conferences, workshops, and/or training
activities to facilitate the adoption of cell line authentication
standards (Nardone 2007).
As the requirement for cell authentication is adopted by
granting agencies and scientific journals, the need for
standardized methods and expectations regarding authenti-
cation itself to be defined becomes more critical. Recog-
nizing this, an effort to prepare a consensus standard on
authentication of human cells was initiated.
The Concept of the Consensus Standard
The idea of the consensus standard is to allow a greater
input from the overall international biomedical community
into standards. The derivation of a standard through the
consensus process improves the chance of universal
voluntary acceptance. In turn, that acceptance will foster
reproducibility and comparability of research employing
human cells. Such a consensus-driven standard, if univer-
sally adopted, should ultimately lead to a marked decrease
in the misidentification of human cells used by the
biomedical community.
The ATCC® Standards Development Organization
The mission of the ATCC
® Standards Development
Organization (SDO) is to develop best practices (standards)
for use in the life science industry and to promote their
global use, using a consensus-driven process that balances
the viewpoints of the stakeholder community. Membership
is free and open to all stakeholders in the biomedical
community, including those involved in the development,
production, application, and regulation of life science
products. Stakeholders include, but are not limited to,
members from academia, government, regulatory, and
industry. All members are participants in the consensus
review, comment, and voting process.
In 2007, the SDO became the first biological resource
organization to become an American National Standards
Institute (ANSI)-accredited standards development organi-
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standards developers meet requirements for openness,
balance, consensus, and due process.
The standard development process employed by the
ATCC
® SDO is shown in Fig. 1.
ATCC SDO Workgroup ASN-0002
ATCC® SDO workgroup ASN-0002 “Development of a
consensus standard for the authentication of human cells:
standardization of STR profiling” was formally assembled
in early 2009 as a result of a proposal submitted in 2008 by
John Masters and Roland Nardone. The workgroup
constitutes an international group of concerned and expe-
rienced scientists. Chaired by Masters, the workgroup
includes individuals with relevant and current experience
in DNA profiling technologies, as well as “stakeholders” or
representatives from major cell repositories, industry,
academia, and government agencies.
Preparation of the Standard. Working under the auspices
of the ATCC SDO, the ASN-0002 workgroup has met
monthly since early 2009. The overall effort was divided
between two subgroups which have met independently at
monthly or more frequent intervals.
The first subgroup is charged with drafting the introduc-
tion to the Standard, defining what is meant by “human cell
line authentication,” describing the historical aspects, from
early discovery of cell line misidentification through to the
present efforts encouraging remediation of the problem.
The subgroup also is delineating the causes of cell line
misidentification, surveying the existing technologies for
cell line authentication, and providing the rationale for
selection of STR profiling for the Standard. The subgroup
is chaired by Raymond Nims.
The second subgroup, chaired by Yvonne Reid, is
fleshing out the procedural details of the general protocol
to be recommended for STR profiling. This subgroup is
also responsible for determining the format and structure
of an associated public database of STR profiles of
ATCC
® SDO Standards Development Process Flowchart 
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Appeals 
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Changes 
Normal Process    Substantive Changes     Appeals   
    *ANS = American National Standard 
ATCC SDO submits Project Initiation
Notification System (PINS) information to
ANSI
ATCC SDO responds to comments from 
PINS, Recommendation for Work Group 
Chair sent to Steering Committee for 
balloting. 
ATCC SDO Consensus Standards
Partnership (CSP) recommends new or
revised standard
Recommendations forwarded to ATCC
SDO Steering Committee (SC) for review,
prioritization and balloting 
Workgroup established and proceeds to
draft ANS* standard
PINS published in ANSI Standards Action 
for 30-day public comment period 
concurrent with CSP Review 
Workgroup forwards draft standard to 
Steering committee for internal review, edits 
and then forwards to ANSI and CSP for 
concurrent 45 day public review and balloting 
Internal & Public 
Comment and balloting 
Workgroup reviews and responds to all 
comments, resolves differences & notifies 
unresolved objectors of their right to appeal 
ATCC SDO submits Standard to ANSI 
Board of Standards Review for final action 
to publish as an ANS standard 
Figure 1. ATCC SDO standards development process flowchart.
730 BARALLON ET AL.human cell lines. Such a database is indispensable with
regard to the establishment of a set of global reference
STR profiles for human cell lines and critical in support
of the Standard.
Methodology. STR profiling was selected as the recom-
mended authentication technology for inclusion in this
Standard primarily because it is capable of resolving
human cells to the individual level. In contrast, histori-
cally important authentication technologies such as
karyotyping, isoenzyme analysis, immunotyping, and
human leukocyte antigen typing do not have sufficient
resolving (discriminating) power to enable unambiguous
authentication of human cells to the individual level (see
ATCC SDO Workgroup ASN-0002 2010 for a more
detailed discussion of the relative discriminating power of
these technologies). In addition, the STR profiling
technology is commercially available in kit form and is
rapid and economical. Masters et al. (2001)d e m o n s t r a t e d
that the technology can provide a universal reference
standard for human cell lines. The STR profiling technol-
ogy, as normally used, detects only human cells, and
therefore additional methods may need to be used to detect
contamination with non-human cells. There are a number
of different commercial kits now available for STR
profiling, and the users will be encouraged to follow the
protocol specific to the kit being used and to refer to the
Standard for additional methodologicalinformation.The most
important aspects of the Standard will be the discussions on
the numbers and types of loci to be evaluated, quality control
of the data, interpretation of the results (matching criteria, loss
of alleles, etc.), and implementation of a universal STR
database.
Associated database. Associated with the issuance of the
Standard will be the construction of a comprehensive and
continuously updatable public database of STR profiles
b a s e do nr e s u l t ss u b j e c tt oa greed-upon interpretation
guidelines and quality control parameters. Comparison of
STR profiles generated from individual cell stocks to such a
database will help reduce the frequency of misidentification
of human cells, enhance confidence in results, assure the
user’s ability to compare scientific results between labora-
tories, and verify that important data originated from
intended samples. STR profiles submitted to the database
may, at the request of the user, be verified by staff at the
National Institutes of Standards and Technology (NIST).
The user also will have the option of submitting STR
profiles to the database without verification. The database
will indicate which profiles have been verified by NIST.
The STR database will be established and maintained under
the auspices of the National Center for Biotechnology
Information and NIST.
Timeline for completion of the Standard. The Standard,
once drafted, will be submitted to the SDO Steering
Committee for initial review (Fig. 1). After a nominal
14-d review period, the ASN-0002 workgroup will have a
chance to respond to any comments provided by the
Steering Committee. At this point, the Standard will be
submitted for public review and comment. ANSI notifies
the public via its weekly publication “ANSI Standards
Action.” Concurrent with this, the Standard will be sent to
all ATCC SDO members for review and comment. At the
end of the 45-d public review and comment period, the
workgroup will review and respond to all negative com-
ments, resolve differences, and notify unresolved objectors
of their right to appeal, if necessary.
The final document will be submitted for review and
approval as an American National Standard by the ANSI.
Once the consensus standard has been approved and
published by ANSI, the workgroup will take appropriate
actions to raise awareness throughout the biomedical
community of the existence of the new standard.
Anticipated Flow and Impact
For newly developed human primary cell cultures and cell
lines, including feeder layer-dependent human stem cells
and tumor cells propagated through xenografting, an initial
STR profile should be established on the earliest material,
for example biopsy, frozen tissue, or formalin-fixed
paraffin-embedded tissue. For feeder layer-dependent
human stem cell preparations, DNA amplification and
barcoding (e.g., Cooper et al. 2007), an isoenzyme analysis
assay or an alternative species identification method may
need to be performed to demonstrate that there are no cross-
contaminating mouse feeder cells in the preparation.
Additional testing may also be necessary in the case of
tumor cell isolation from xenografts to demonstrate that
there are no host cells remaining in the recovered tumor cell
line.
For existing human cell lines, investigators will be
encouraged to: (1) check the public database to see if the
cell line is represented within the STR database; (2)
perform an STR profile and compare the results to those
within the STR database; and (3) ensure that the STR
database indicates that this cell line is not misidentified.
The Standard will provide the necessary matching criteria.
Continuous human cell lines which are manipulated
within laboratories employing non-human cell lines may
need to be monitored periodically for non-human cell cross-
contamination using one of the cell species identification
methods mentioned above (isoenzyme analysis or DNA
amplification and barcoding).
RECOMMENDATION OF SHORT TANDEM REPEAT PROFILING 731To the degree to which the Standard is adopted and
complied with, issuance of the Standard will have a
significant beneficial impact on the quality and validity of
research based upon the use of human cells.
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